Clinical Trial Update: Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating tiotropium 2.5 and 5 mcg once daily via the Respimat inhaler against placebo and salmeterol MDI in adults with moderate persistent as…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Salmeterol (salmeterol)
• tiotropium (tiotropium)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2014-02-07